TY - JOUR
T1 - Measuring cognition and function in the preclinical stage of Alzheimer's disease
AU - Weintraub, Sandra
AU - Carrillo, Maria C.
AU - Farias, Sarah Tomaszewski
AU - Goldberg, Terry E.
AU - Hendrix, James A.
AU - Jaeger, Judith
AU - Knopman, David S.
AU - Langbaum, Jessica B.
AU - Park, Denise C.
AU - Ropacki, Michael T.
AU - Sikkes, Sietske A.M.
AU - Welsh-Bohmer, Kathleen A.
AU - Bain, Lisa J.
AU - Brashear, Robert
AU - Budur, Kumar
AU - Graf, Ana
AU - Martenyi, Ferenc
AU - Storck, Marta Segardahl
AU - Randolph, Christopher
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
AB - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
UR - http://www.scopus.com/inward/record.url?scp=85042848973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042848973&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042848973&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29955653
U2 - https://doi.org/10.1016/j.trci.2018.01.003
DO - https://doi.org/10.1016/j.trci.2018.01.003
M3 - Short survey
C2 - 29955653
SN - 2352-8737
VL - 4
SP - 64
EP - 75
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
ER -
